Filter posts

Worldwide Orphan Drug Market to Grow to $127 Billion by 2018

The 2013 Orphan Drug Report from Evaluate, which launched today at the 2013 BIO international …

Expanding Access to Orphan Drugs

At present many orphan diseases do not have any licensed treatments, and for those conditions …

A Bright Future for Orphan Disease Indications

In celebration of National Rare Disease Day BIO’s Industry Analysis team took a look at recently-approved …

Navigating the Rare Disease World

The international orphan drug marketplace is expected to grow some 30 percent by 2014, fueled …

Orphan Drugs: Making Rare Diseases Rarer

A panel at the BIO CEO & Investor Conference provided an analysis of the thriving …

FDASIA: A Step Forward for Patients

Earlier this year, Congress passed and President Obama signed the FDA Safety and Innovation Act …

BIO Investor Forum - Raring to Go: The Race to Treat Ultra-Rare Diseases

The signing of FDASIA by President Obama in July reinforces the country’s commitment to fostering …

FDA Safety and Innovation Act: A Step Forward for Patients With Rare Diseases

By Peter L. Saltonstall, President and CEO, National Organization for Rare Disorders (NORD) The Food …

2012 Orphan Disease Forum: Addressing Today’s Opportunities and Challenges

If all of the people with rare disease lived in one country, it would be …